Clinical trial
A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer
NCT01891357 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer
- Lead sponsor
- Women's Cancer Study Group GmbH
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2013
- Completion date
- November 16, 2016
- Enrollment
- 64 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.